Today: 30 January 2026
Subscribe
Browse Category

NASDAQ:CYTK News 22 December 2025 - 1 January 2026

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance The year-end move keeps focus on…
1 January 2026
·····
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

NEW YORK, December 31, 2025, 14:52 ET — Regular session Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500 tracker and Nasdaq 100 fund were both down about 0.4% to 0.5%. The move matters because Cytokinetics is nearing its…
31 December 2025
·····
Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics, Incorporated (NASDAQ: CYTK) surged on Monday, December 22, 2025, extending a sharp rally that followed the company’s first-ever U.S. drug approval. Shares traded around $69.68 in the session, up roughly 11% from the prior close, after reaching an intraday high near $70.86—a move that pushed the biotech to fresh 52-week highs and re-focused Wall Street on the commercial potential…
22 December 2025
·····

Stock Market Today

  • NSE Gets SEBI Nod to Proceed with IPO, Clearing Major Regulatory Hurdle
    January 30, 2026, 9:36 AM EST. India's National Stock Exchange (NSE) has secured a no-objection certificate from the Securities and Exchange Board of India (SEBI) to initiate its initial public offering (IPO). This approval allows NSE to appoint merchant bankers and prepare the draft red herring prospectus, a preliminary document for regulatory review. Though final clearance is pending, the nod signals progress after years of regulatory scrutiny related to governance and trading practices. The IPO, one of the largest anticipated in India's capital markets, aims to broaden investor participation and offer exit options to current shareholders. Market watchers expect the process to extend over several months, with details on size, valuation, and timing yet to be disclosed.
Go toTop